<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890955</url>
  </required_header>
  <id_info>
    <org_study_id>HOG LUN07-130</org_study_id>
    <nct_id>NCT00890955</nct_id>
  </id_info>
  <brief_title>Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies</brief_title>
  <official_title>A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawrence Einhorn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amrubicin has shown single-agent activity in lung cancer. The combination of cyclophosphamide&#xD;
      and anthracyclines has been studied and concluded that the combination was tolerable, could&#xD;
      be given safely, and therapeutically useful.&#xD;
&#xD;
      This Phase I study will evaluate the combination of cyclophosphamide with amrubicin in&#xD;
      relapsed solid tumors and will define the MTD of the combination in a US population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.&#xD;
&#xD;
      This study will follow the 3+3 design with the following dose levels:&#xD;
&#xD;
        -  Dose Level -1: Amrubicin 20mg/m2, Cyclophosphamide 500mg/m2&#xD;
&#xD;
        -  Dose Level 1: Amrubicin 25mg/m2, Cyclophosphamide 500mg/m2&#xD;
&#xD;
        -  Dose Level 2: Amrubicin 30mg/m2, Cyclophosphamide 500mg/m2&#xD;
&#xD;
        -  Dose Level 3: Amrubicin 35mg/m2, Cyclophosphamide 500mg/m2&#xD;
&#xD;
        -  Dose Level 4: Amrubicin 40mg/m2, Cyclophosphamide 500mg/m2&#xD;
&#xD;
      Dose escalation starts from dose level 1.&#xD;
&#xD;
      Amrubicin will be given as a slow IV push or infusion over approximately 5 minutes once daily&#xD;
      for 3 consecutive days starting on day 1 of each 21 day cycle.&#xD;
&#xD;
      Cyclophosphamide will be given at a fixed dose as an IV infusion over 30-60 minutes on day 1&#xD;
      of each 21 day cycle (following amrubicin).&#xD;
&#xD;
      ECOG Performance Status: 0-1&#xD;
&#xD;
      Life expectancy: not specified&#xD;
&#xD;
      Hematopoietic:&#xD;
&#xD;
        -  Hemoglobin (Hgb) &gt; 9 g/dL.&#xD;
&#xD;
        -  Platelets &gt; 100 K/mm3&#xD;
&#xD;
        -  Absolute Neutrophil Count (ANC) &gt; 1.5 K/mm3&#xD;
&#xD;
      Hepatic:&#xD;
&#xD;
        -  Aspartate transaminase (AST) ≤ 2.5 x ULN&#xD;
&#xD;
        -  Alanine transaminase (ALT) ≤ 2.5 x ULN&#xD;
&#xD;
        -  Total bilirubin &lt; 1.5 x ULN&#xD;
&#xD;
      Renal:&#xD;
&#xD;
        -  Calculated creatinine clearance ≥ 60cc/min&#xD;
&#xD;
      Cardiovascular:&#xD;
&#xD;
        -  Left Ventricular Ejection Fraction (LVEF) ≥ LLN for institution within 60 days prior to&#xD;
           registration for protocol therapy.&#xD;
&#xD;
        -  No history of cardiomyopathy or uncontrolled heart arrhythmia.&#xD;
&#xD;
      Pulmonary:&#xD;
&#xD;
        -  No suspected, diffuse idiopathic interstitial lung disease or history of pulmonary&#xD;
           fibrosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of the combination of amrubicin and cyclophosphamide in patients with advanced solid tumors.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the toxicities of the combination of amrubicin and cyclophosphamide in patients with advanced solid tumors.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess response to the combination of amrubicin and cyclophosphamide</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amrubicin + Cyclophosphamide 3+3 design with the following dose levels:&#xD;
Dose Level -1: Amrubicin 20mg/m2, Cyclophosphamide 500mg/m2&#xD;
Dose Level 1: Amrubicin 25mg/m2, Cyclophosphamide 500mg/m2&#xD;
Dose Level 2: Amrubicin 30mg/m2, Cyclophosphamide 500mg/m2&#xD;
Dose Level 3: Amrubicin 35mg/m2, Cyclophosphamide 500mg/m2&#xD;
Dose Level 4: Amrubicin 40mg/m2, Cyclophosphamide 500mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amrubicin</intervention_name>
    <description>Dose Level -1: 20mg/m2&#xD;
Dose Level 1: 25mg/m2&#xD;
Dose Level 2: 30mg/m2&#xD;
Dose Level 3: 35mg/m2&#xD;
Dose Level 4: 40mg/m2&#xD;
Amrubicin will be given as a slow IV push or infusion over approximately 5 minutes once daily for 3 consecutive days starting on day 1 of each 21 day cycle.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide will be given at a fixed dose as 500mg/m2 IV infusion over 30-60 minutes on day 1 of each 21 day cycle (following amrubicin).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced solid organ malignancy that is&#xD;
             refractory to currently available therapies or for which no effective therapy exists.&#xD;
&#xD;
          -  Must have measurable or evaluable disease per RECIST as evaluated by imaging within 30&#xD;
             days prior to registration for protocol therapy.&#xD;
&#xD;
          -  Must have completed chemotherapy at least 28 days prior to registration for protocol&#xD;
             therapy and recovered from the acute toxic effects.&#xD;
&#xD;
          -  Prior radiation therapy is allowed to &lt; 25% of the bone marrow. Patients must have&#xD;
             recovered from the acute toxic effects of radiation prior to registration for protocol&#xD;
             therapy.&#xD;
&#xD;
          -  Must be willing to consent to the blood sample collection for SNP analysis.&#xD;
&#xD;
          -  Females of childbearing potential and males must be willing to use an effective method&#xD;
             of contraception (hormonal or barrier method of birth control; abstinence) from the&#xD;
             time of consent until at least 30 days following completion of protocol therapy.&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test within 7 days&#xD;
             prior to registration for protocol therapy. Patients are considered not of child&#xD;
             bearing potential if they are surgically sterile (they have undergone a hysterectomy,&#xD;
             bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.&#xD;
&#xD;
          -  Written informed consent and HIPAA authorization for release of personal health&#xD;
             information.&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No prior therapy with cyclophosphamide or anthracyclines.&#xD;
&#xD;
          -  No treatment with any investigational agent within 28 days prior to registration for&#xD;
             protocol therapy.&#xD;
&#xD;
          -  No suspected, diffuse idiopathic interstitial lung disease or history of pulmonary&#xD;
             fibrosis.&#xD;
&#xD;
          -  No evidence of severe or uncontrolled other systemic disease or any concurrent&#xD;
             condition which in the investigator's opinion makes it undesirable for the patient to&#xD;
             participate in the trial or which would jeopardize compliance with the protocol.&#xD;
&#xD;
          -  No symptomatic brain metastases. Patients with treated brain metastasis must be off&#xD;
             steroids and must have completed radiation at least 21 days prior to registration for&#xD;
             protocol therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Einhorn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hoosier Cancer Research Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72764</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen F. Graham Cancer Center</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical &amp; Surgical Specialists, LLC</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center of Southern Indiana</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Consultants, P.C.</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Cancer Research Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center Extramural Research Program</name>
      <address>
        <city>Rockledge</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hoosieroncologygroup.org</url>
    <description>Hoosier Oncology Group Homepage</description>
  </link>
  <results_reference>
    <citation>Jalal SI, Hanna N, Zon R, Masters GA, Borghaei H, Koneru K, Badve S, Prasad N, Somaiah N, Wu J, Yu Z, Einhorn L. Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130. Am J Clin Oncol. 2017 Aug;40(4):329-335. doi: 10.1097/COC.0000000000000160.</citation>
    <PMID>25503432</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>April 29, 2009</study_first_submitted>
  <study_first_submitted_qc>April 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2009</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hoosier Cancer Research Network</investigator_affiliation>
    <investigator_full_name>Lawrence Einhorn</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Solid tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Amrubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

